PF-06954522 IR (Formulation 1)
DrugParticipants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth
NCT Number: NCT06393517
The purpose of this study is to compare three finished products of PF-06954522 in terms of the uptake into the blood stream.
This study is seeking participants who are:
- Healthy male or female participants aged 18 years or older.
All participants in this study will receive PF-06954522 once by mouth. The participants may receive different tablets by mouth for PF-06954522.
The study will compare experiences of people receiving three different products of PF-06954522. This will help understand how much PF-06954522 is taken up into the blood for each product given.
Participants will take part into the study for about 77 days. During this time participants will have to stay onsite for 21 days. There will be one follow up (by telephone) study visit.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
Pfizer Clinical Research Unit, New Haven, Connecticut, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth
Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.
Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth
Time frame: 0 hours (pre-dose) to 72 hours (extrapolated to infinite time) post PF-06954522 dose in each period
Time frame: 0 hours (pre-dose) to 72 hours post PF-06954522 dose in each period
Time frame: From baseline up to 49 days after PF-06954522 dose in Period 1 Day 1
Time frame: From baseline up to 72 hours after PF-06954522 dose in each period
Time frame: From baseline up to 72 hours after PF-06954522 dose in each period
Time frame: From baseline up to 72 hours after PF-06954522 dose in each period
Time frame: 0 hours (pre-dose) to 72 hours (extrapolated to infinite time) post PF-06954522 dose in each period
Time frame: 0 hours (pre-dose) to 72 hours post PF-06954522 dose in each period
Pfizer
Industry
A PHASE 1, OPEN-LABEL, RANDOMIZED, 5-PERIOD, 6-SEQUENCE, CROSSOVER STUDY TO COMPARE THE SINGLE-DOSE PHARMACOKINETICS OF IMMEDIATE-RELEASE AND MODIFIED-RELEASE FORMULATIONS OF PF-06954522 ADMINISTERED ORALLY TO HEALTHY ADULT PARTICIPANTS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05870072
Balance, Postural, Behavior
Kütahya, Centre, Turkey (Türkiye)
View Trial DetailsNCT07241065
Healthy Participants
Berlin, Germany
View Trial DetailsNCT07214766
Healthy Participants
Anaheim, California, United States
View Trial DetailsNCT07444424
Body Weight, Diabetes Mellitus
Fukuoka, Japan
View Trial Details